(BMSIC/DRUGS/15-05)		
S.N.	*Technical Eligibility Criteria as per NIT*	***Name of Bidder:Zee Laboratories Ltd.*** ***Corporate Address:Uchani, G.T.Road, Karnal-132001*** ***MU Address: Behind 47, Industrial Area, Paonta Sahib-173025*** ***"Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-156) "***
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	Fresh Certificate of Incorporation Consequent on change of name submitted wherein the name of the company is Zee herbal laboratories Limited (Page 126) ; Certificate of Incorporation is in the name of Zee herbal laboratories Private Limited (Pg -125); Certifcate of Incorporation dated 25.04.2008 in the name of Zee Laboratories Ltd. Submitted (Page - 127) MOA and AOA is in the name of Zee laboratories limited submitted (Page- 93-124)
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Self attested copy of resolution passed at the Fifth meeting of the board of Directors of the company resolved that Mr. Puneet Sharma, is hereby authorised to take all such steps and to execute all such documents, declare affidavits etc., which will be necessary for the purposes of the abovesaid Resolution, (Page No.92)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	List of quoted item(Products NIT Sr.No.- 6,7,9,10,16,17,18,26,36,44,46,51,52,55,56,58,59,64,65,75,76,79,91,105,118,129,138,142,143,147,148,150,151,152,153,154,157,165,166,167,187,188,198,199,200,208 & 209 (47 Items) submitted in Prescribed format as per Annexure - III. (Page No.87-91)
4	• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	Copy Of Manufacturing Licence in Form-25 & 28 Submitted bearing M.L No. S-MNB/10/67 and S-MB/10/68 issued date 26/02/2010. (Pg. - 85 - 86) Renewal in Form -26 bearing M.L No. - Form - 25: S-MNB/10/67 and Form - 28: S-MB/10/68 valid upto25/02/2020, submitted (Pg. - 84) Quoted product approval for NIT S.No- 6,7,9,10,16,17,18,26,36,44,46,51,52,55,56,58,59,64,65,75,76,79,91,105,118,129,138,142,143,147,148,150,151,152,153,154,157,165,166,167,187,188,198,199,200,208 & 209 submitted. (Pg No 47-83). Quoted product details mentioned in enclosure-
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	The submitted self attested copies of MSC's which states that the bidder firm's licence is renewed upto 25.02.2020 and are manufacturing and marketing the products mentioned in the lists of the MSCS' since last three years and the quoted products NIT Sl. No. mentioned below are in the certificate:- 118, 36, 75, 76, 06, 44, 143, 151, 07, 16, 18, 26, 46, 51, 52, 157, 148, 166, 167, 150, 09, 10, 79, 105, 138, 147, 158 & 208. (28 Items) (Pg. - 39 - 45, 37 & 30) The submitted MSC'S which states that the bidders firm's licence which is valid upto 25.02.2015 are manufacturing and marketing the products mentioned in the lists of the MSCS' since last three years and the quoted products NIT Sl. No. mentioned below are in the certificate:- 55, 64, 152, 187, 129, 142, 153, 188, 17, 58, 59, 65, 165, 199, 154, 56, 91, 200 & 209. (19 Items) (Pg. - 31 - 36 & 38) Self attested copy of MSC submitted for the quoted products the details of which is enclosed.
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self Attested Copy of Non Conviction Certificate wherein it is stated that the said firm has not been convicted under the provision of the Drugs and cosmetics Act, 1940 and Rules 1945 made there under, in the State of Himachal Pradesh, from the day of grant of licenses submitted issued by Assistant Drugs Controller cum drugs licensing Authority, regional hospital complex, Distt. Sirmour- HQ at Nahan (HP) Vide Letter no-DCA/SLN/DML/N(ADC)86/10/707 dated 24/03/2015 (Pg. No.29)

8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self Attested copy of GMP Certificate as per revised Schedule - M of Drugs & Cosmetics Rules, 1945 wherein it is stated that this certificate is valid upto 29/05/2017 submitted issued by Assistant Drugs Controller cum drugs licensing Authority, regional hospital complex, Distt. Sirmour- HQ at Nahan (HP) Vide Letter no-DCA/SLN/DML/86/10/1364 dated 30/05/2015 for the following catogries of Drugs Tablets and Capsules (beta-lactam, General, hormonal & anti cancer only); Dry Syrups (beta-lactam & general only); Liquid Orals, Ointments, External Preparations and soft gelatin Capsules (genneral category only); Small Volume Injectables (Liquid ampoules & Liquid Ophthalmic preparations) and Dry Injectables (general category): Small Volume Injectables (beta-lactam and Cephalosporins dry powders only); Small Volume Injectables liquid, sex hormones and SVP anti cancer, liquid vials, liquid Ampoules and Dry Injectables only. (Pg. No.28)
9	Self attested copies of Maximum Batch Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self Attested Copy of Production Capacity certificate wherein Section wise annual capacity (Units in Lacs) (Single Shift of 8 Hours) is mentioned submitted issued by Drugs licensing Authority, Drugs Control Admn. HP, Solan Vide Letter no-DCA/SLN/DML/86/10/404 dated 13/02/2013 (Pg. No.27)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Affidavit for Non-Blacklisting of the firm & its quoted product by the authorised signatory submitted as per Annexure II of NIT (Pg.No.25-26)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	Rs. 5,00,000/-, BG No.-2015-16 120, State Bank of India
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	Rs. 10,000/-, DD No.- 239339 , State Bank of India
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y.- 2011-12, P-24-22 Rs. 56.31 Crore F.Y. -2012-13 P-21-19 Rs. 91.50Crore F.Y. 2013-14 P-18-16 Rs. 138.88 Crore
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A.Y.- 2012-13 P- 14 A.Y.- 2013-14 P-13 A.Y.- 2014-15 P- 12
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	P-11
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	P-10
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Copy of Affidavit (Acceptance of tender conditions)Submitted as per Annexure IV of NIT (Pg.No.6)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. Inspite, some inadvertent dicrepencies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepencies is observed, for rectification.

	The facts in pages mentioned against the clause No-1 to 10 and 17 of this chart has been verified.	

Zee Laboratories

PRODUCT LIST APPROVAL & MARKET STANDING STATUS

Sl.no.	NIT S No	Product Name	Product Approval Date/Validity(Pg No.)/S.No.	Remarks	Market Standing for more than three years (Pg No)/Sl.no	Remarks
1	6	Albendazole Oral Suspension IP 200 mg / 5 ml - 10 ml bottel	26.02.10/25.02.2015, 83/01		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(37/1)**	Pack size not specified.
2	7	Albendazole Tab. IP 400 mg	26.02.10/25.02.2015, 82/03		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/4)**	
3	9	Amikacine Inj. IP 100 mg / 2 ml - 2 ml vial	27.02.2010/25.02.2015, 81/01		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(42/4)**	Pack size not specified.
4	10	Amikacin Injection IP 250 mg / 2 ml - 2 ml vial	27.02.2010/25.02.2015, 81/02		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(42/5)**	Pack size not specified.
5	16	Amoxycillin Capsule IP 500 mg	26.02.10/25.02.2015, 80/04		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/3)**	
6	17	Amoxycillin Capsule IP 250 mg	26.02.10/25.02.2015, 80/03		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(34/9)**	
7	18	Amoxycillin Dispersible Tab. IP 125 mg	Effective from 21/12/2010, 79/08		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/2)**	
8	26	Atenotol Tablets IP 50 mg	26.02.10/25.02.2015, 78/08		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/6)**	
9	36	Calcium Tablets (Each tablet Contains : Calcium Carbonate equivalent to 500 mg elemental calcium and Vit D3 - 250 I.U.)	25.03.2010/25.02.2015, 77/08		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(43/8)**	
10	44	Cefixime Tablets IP 100 mg	26.02.10/25.02.2015, 76/04		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(37/5)**	

11	46	Cefotaxime Sodium Injection IP 1 gm vial	26.02.10/25.02.2015, 75/07		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/7)**	
12	51	Ceftazidime Injection IP 250 mg	25.03.2010/25.02.2015, 74/05		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/10)**	
13	52	Ceftazidime Injection IP 1 g	05.03.2010/25.02.2015, 74/04		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/8)**	
14	55	Ceftriaxone Injection IP 250 mg vial	05.03.2010/25.02.2015, 73/17		Manufacturing and Marketing Certificate, vide Letter No. 368, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 30/05/2015 **(38/1)**	
15	56	Ceftriaxone Injection IP 500 mg vial	05.03.2010/25.02.2015, 73/16		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(31/5)**	
16	58	Cetrizine Hydrochloride Tablets IP 10 mg	27.02.2010/25.02.2015, 72/42		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(34/5)**	
17	59	Cetrizine Syrup IP 5 mg / 5 ml - 30 ml	10.03.2010/25.02.2015, 71/10		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(33/1)**	Pack size not specified.
18	64	Ciprofloxacin Eye Drops IP 0.3% w/v - 5ml Pack	Effective from 21/01/2011, 70/12		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(38/8)**	Pack size not specified.
19	65	Ciprofloxacin Hydrochloride Tablets IP 250 mg	26.02.10/25.02.2015, 78/09		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(33/10)**	
20	75	Dexamethasone Injection IP 4mg/ml 2ml vial	01.09.11/25/02/2015, 69/02		Manufacturing and Marketing Certificate, vide Letter No. 876 dated 10-04-15, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority. **(41/10)**	Pack size not specified.

21	76	Dexamethasone Injection IP 4mg/ml 10ml vial	01.09.11/ 25.02.15, 69/2	Pack size not as per NIT	Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(41/10)**	Pack size not specified.
22	79	Diclofenac Gel 1% w/w - 30 gm	26.02.10/25.02.2015, 68/07		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/6)**	Pack size not specified.
23	91	Fluoxetine capsules IP 20mg	26.02.10/25.02.2015, 67/03		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(31/2)**	
24	105	Hydrocortisone Sodium Succinate Injection IP 100 mg	05.03.2010/25.02.2015, 66/06		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/3)**	
25	118	Levocetirizine Dihydrochloride Syrup 2.5mg/5ml, 30ml bottle	10.03.2010/25.02.2015, 65/28		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(45/01)**	Pack size not specified.
26	129	Meropenem Injection IP 1000 mg	25.03.2010/25.02.2015, 64/10		Manufacturing and Marketing Certificate, vide Letter No 2734, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 **(35/3)**	
27	138	Micronized Progesterone Soft gelatin Capsule 200 mg	10.03.2010/25.02.2015, 63/67		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/10)**	
28	142	Misoprostol Tablet IP, 200 microgram, 10*10	27.02.2010/25.02.2015, 62/06	Product specification in **B.P,** as per NIT, it is **I.P.**	Manufacturing and Marketing Certificate, vide Letter No. 2734, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 **(35/4)**	Product specification in **B.P,** as per NIT, it is **I.P.**
29	143	Moxifloxacin Eye Drops IP 0.5% w/v - 5 ml Pack	26.02.10/25.02.2015, 61/04		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(37/4)**	Pack size not specified.
30	147	Norethisterone Tablets 5mg, 10*10	27.02.2010/25.02.2015, 60/04		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/4)**	
31	148	Ofloxacin and Ornidazole suspension, 50mg&125mg/5ml, 30ml bottle	06/12/2010/ validity not mentioned, 59/05		Manufacturing and Marketing Certificate, vide Letter No. 2627, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/09/2015 **(30/10)**	Pack size not specified.
32	150	Ofloxacin Ophthalmic Solution IP 0.3% w/v - 10 ml Pack	26.02.10/25.02.2015, 58/07		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(44/4)**	Pack size not specified.

33	151	Ofloxacin Oral Suspension IP 50 mg / ml - 30 ml	26.02.10/25.02.2015, 57/05		Manufacturing and Marketing Certificate, vide Letter No. 878, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/04/2015 **(37/2)**	Pack size not specified.
34	152	Ondansetron Hydrochloride Injection 2 mg / ml - 2 ml. Amp.	05.03.2010/25.02.2015, 56/32		Manufacturing and Marketing Certificate, vide Letter No. (not clear), signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 **(36/5)**	Pack size not specified.
35	153	Ondansetron Oral Solution IP 2 mg / 5 ml - 30 ml	10.03.2010/25.02.2015, 55/39	Brand name approval under USP specification and composition under IP specification.	Manufacturing and Marketing Certificate, vide Letter No. (not clear), signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 **(35/10)**	Pack size not specified.
36	154	Ondansetron Tablets IP 4 mg	27.02.2010/25.02.2015, 54/79		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(32/9)**	
37	157	Pantoprazole for injection, 40mg vial	26.02.10/25.02.2015, 75/09		Manufacturing and Marketing Certificate, vide Letter No. 2287, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(39/9)**	
38	165	Piperacillin & Tazobactum for Injection (Piperacillin 4 gm & Tazobactum 500 mg) - 4.5 gm vial	05.03.2015/25.02.2015, 53/24		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(33/8)**	
39	166	Povidone - Iodine Ointment (5%w/w (0.5% w/w available iodine)) - 15 gm Tube	26.02.10/25.02.2015, 68/05		Manufacturing and Marketing Certificate, vide Letter No. 2627, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/09/2015 **(30/7)**	Pack size not specified.
40	167	Povidone - Iodine Solution IP 5%w/v - 500 ml Pack	26.02.10/25.02.2015, 52/04	Pack size 500ml not mentioned & approval for 50, 60, 100 & 200ml whereas NIT pack size specification is 500ml.	Manufacturing and Marketing Certificate, vide Letter No. 2627, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 10/09/2015 **(30/8)**	Pack size not specified.
41	187	Sodium Valporate Tab IP 500mg, 10*10	27-02-10/25-02-15, 51/94	Approval for sodium valproate IP 333 mg & valproic acid USP 145 mg whereas NIT specification is sodium valporate IP 500mg.	Manufacturing and Marketing Certificate, vide Letter No. (not clear), signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 (36/3)	MSC for sodium valporate and valproic acid tablet whereas NIT specification is of sodium valporate only.

42	188	Sodium Valporate Tab IP 500mg, 10*10	27-02-10/25-02-15, 51/93	Approval for sodium valproate IP 333 mg & valproic acid USP 58 mg whereas NIT specification is sodium valporate IP 200mg.	Manufacturing and Marketing Certificate, vide Letter No. (not clear), signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 16/12/2014 **(35/7)**	MSC for sodium valporate and valproic acid tablet whereas NIT specification is of sodium valporate only.
43	198	Tramadol Hydrochloride Injection 50 mg / ml - 2 ml. Amp.	27.02.2010/25.02.2015, 50/09		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/7)**	Pack size not specified.
44	199	Tranexemic acid injection IP, 100mg/ml, 5ml amp.	27.02.2010/25.02.2015, 50/08	Product specification in **B.P,** as per NIT, it is **I.P.**	Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(32/4)**	MSC under BP specification.
45	200	Tranexemic acid tablets IP, 500mg	27.02.2010/25.02.2015, 49/11	Product specification in **B.P,** as per NIT, it is **I.P.**	Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(31/10)**	Product specification in **B.P,** as per NIT, it is **I.P.**
46	208	Xylometazoline Nasal Drops IP 0.1% w/v - 10 ml	05.03.2010/25.02.2015, 48/40		Manufacturing and Marketing Certificate, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 24/08/2015 **(40/8)**	Pack size not specified.
47	209	Xylometazoline Nasal Drops IP 0.05% w/v - 10 ml	05.03.2010/25.02.2015, 47/39		Manufacturing and Marketing Certificate, vide Letter No. 2244, signed by Asst. Drugs Controller-Cum-drugs Licensing Authority on 14/10/2015 **(31/1)**	Pack size not specified.

NOTE: On Certificate of Renewal of License (Pg. No. 84), it is mentioned on S.No. 3: Name of drugs: As permitted for General Category- Tablets, Capsules and dry Syrups, Liquid Orals, ointments, External preparations, soft gelatin capsules, Liquid vials and ampoules, Opthalmic preparation& eye ointments is mentioned.